Journal Information
Vol. 31. Issue 3.
Pages 255-261 (March 2012)
Share
Share
Download PDF
More article options
Vol. 31. Issue 3.
Pages 255-261 (March 2012)
Editors’ network
DOI: 10.1016/j.repce.2012.02.003
Open Access
Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology
Almanaque de 2011: miocardiopatias. As revistas das sociedades cardiológicas nacionais apresentam investigação seleccionada que levou a avanços recentes na cardiologia clínica
Visits
...
Perry M. Elliotta,b, Saidi A. Mohiddina,b,??
Corresponding author
smohiddin@doctors.org.uk

Corresponding author.
a The Heart Hospital, London, UK
b Department of Cardiology, The London Chest Hospital, London, UK
Article information
Full text is only aviable in PDF
References
[1]
A.A. Hagege, E. Caudron, T. Damy, et al.
Screening patients with hypertrophic cardiomyopathy for fabry disease using a filter-paper test: the focus study.
Heart, 97 (2011), pp. 131-136
[2]
I. Olivotto, B.J. Maron, E. Appelbaum, et al.
Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy.
Am J Cardiol, 106 (2010), pp. 261-267
[3]
R. O’Hanlon, A. Grasso, M. Roughton, et al.
Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.
J Am Coll Cardiol, 56 (2010), pp. 867-874
[4]
O. Bruder, A. Wagner, C.J. Jensen, et al.
Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.
J Am Coll Cardiol, 56 (2010), pp. 875-887
[5]
A.S. Flett, M.P. Hayward, M.T. Ashworth, et al.
Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans.
Circulation, 122 (2010), pp. 138-144
[6]
C.Y. Ho, B. Lopez, O.R. Coelho-Filho, et al.
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.
N Engl J Med, 363 (2010), pp. 552-563
[7]
Ingles J, McGaughran J, Scuffham PA, et al. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart. 2011 Nov 29. [Epub ahead of print]. PMID: 22128210. doi:10.1136/heartjnl-2011-300368.
[8]
S. Wordsworth, J. Leal, E. Blair, et al.
DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.
Eur Heart J, 31 (2010), pp. 926-935
[9]
S. Agarwal, E.M. Tuzcu, M.Y. Desai, et al.
Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy.
J Am Coll Cardiol, 55 (2010), pp. 823-834
[10]
F.J. Ten Cate, O.I. Soliman, M. Michels, et al.
Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution.
Circ Heart Fail, 3 (2010), pp. 362-369
[11]
R.A. Nishimura, S.R. Ommen.
Septal reduction therapy for obstruc-tive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you.
Circ Cardiovasc Interv, 3 (2010), pp. 91-93
[12]
R.A. Leonardi, E.P. Kransdorf, D.L. Simel, et al.
Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment.
Circ Cardiovasc Interv, 3 (2010), pp. 97-104
[13]
T. Lawrenz, B. Borchert, C. Leuner, et al.
Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months’ follow-up in 19 patients.
J Am Coll Cardiol, 57 (2011), pp. 572-576
[14]
E. Galve, A. Sambola, G. Saldana, et al.
Late benefits of dualchamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study.
Heart, 96 (2010), pp. 352-356
[15]
S.A. Mohiddin, S.P. Page.
Long-term benefits of pacing in obstructive hypertrophic cardiomyopathy.
Heart, 96 (2010), pp. 328-330
[16]
J.M. Bos, B.J. Maron, M.J. Ackerman, et al.
Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.
Am J Cardiol, 106 (2010), pp. 1481-1486
[17]
I. Christiaans, K. van Engelen, I.M. van Langen, et al.
Risk stratification for sudden cardiac death in hypertrophic car-diomyopathy: systematic review of clinical risk markers.
Europace, 12 (2010), pp. 313-321
[18]
O’Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic car-diomyopathy. Heart. Published Online First: 13 July 2011. doi:10.1136/hrt.2010.217182.
[19]
J.P. Kaski, P. Syrris, M.T. Esteban, et al.
Prevalence of sarcom-ere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy.
Circ Cardiovas Genet, 2 (2009), pp. 436-441
[20]
Moak JP, Leifer ES, Tripodi D, et al. Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events. Pediatr Cardiol. Published Online First: 13 April 2011. PMID: 21487794.
[21]
D. Gao, N. Ning, X. Niu, et al.
Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
Heart, 97 (2011), pp. 278-286
[22]
K. Abozguia, P. Elliott, W. McKenna, et al.
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
Circulation, 122 (2010), pp. 1562-1569
[23]
D. Corrado, C. Basso, K. Pilichou, et al.
Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Heart, 97 (2011), pp. 530-539
[24]
F.I. Marcus, W.J. McKenna, D. Sherrill, et al.
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria.
Eur Heart J, 31 (2010), pp. 806-814
[25]
V. Fressart, G. Duthoit, E. Donal, et al.
Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: spectrum of mutations and clinical impact in practice.
Europace, 12 (2010), pp. 861-868
[26]
Otten E, Asimaki A, Maass A, et al. Desmin mutations as a cause of right ventricular heart failure affect the intercalated disks. Heart Rhythm. 2010; 7:1058-1064, the official journal of the Heart Rhythm Society.
[27]
B. Klauke, S. Kossmann, A. Gaertner, et al.
De novo desmin-mutation n116s is associated with arrhythmogenic right ventricular cardiomyopathy.
Hum Mol Genet, 19 (2010), pp. 4595-4607
[28]
M. Taylor, S. Graw, G. Sinagra, et al.
Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syn-dromes.
Circulation, 124 (2011), pp. 876-885
[29]
J.D. Kapplinger, A.P. Landstrom, B.A. Salisbury, et al.
Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise.
J Am Coll Cardiol, 57 (2011), pp. 2317-2327
[30]
M.G. Cox, P.A. van der Zwaag, C. van der Werf, et al.
Arrhythmo-genic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dys-plasia/cardiomyopathy genotype-phenotype follow-up study.
Circulation, 123 (2011), pp. 2690-2700
[31]
G. Quarta, A. Muir, A. Pantazis, et al.
Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria.
Circulation, 123 (2011), pp. 2701-2709
[32]
N. Protonotarios, A. Anastasakis, L. Antoniades, et al.
Arrhythmo-genic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmo-somal mutations.
Eur Heart J, 32 (2011), pp. 1097-1104
[33]
A. La Gerche, C. Robberecht, C. Kuiperi, et al.
Lower than expected desmosomal gene mutation prevalence in endurance athletes with complex ventricular arrhythmias of right ventric-ular origin.
Heart, 96 (2010), pp. 1268-1274
[34]
G. Quarta, D. Ward, M.T. Tome Esteban, et al.
Dynamic electro-cardiographic changes in patients with arrhythmogenic right ventricular cardiomyopathy.
Heart, 96 (2010), pp. 516-522
[35]
D. Corrado, H. Calkins, M.S. Link, et al.
Prophylactic implantable defibrillator in patients with arrhythmogenic right ven-tricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
Circulation, 122 (2010), pp. 1144-1152
[36]
S.A. Wiltshire, G.A. Leiva-Torres, S.M. Vidal.
Quantitative trait locus analysis, pathway analysis, and consomic mapping show genetic variants of tnni3k, fpgt, or h28 control susceptibility to viral myocarditis.
J Immunol, 186 (2011), pp. 6398-6405
[37]
C. Gorbea, K.A. Makar, M. Pauschinger, et al.
A role for toll-like receptor 3 variants in host susceptibility to enterovi-ral myocarditis and dilated cardiomyopathy.
J Biol Chem, 285 (2010), pp. 23208-23223
[38]
B.D. Horne, K.D. Rasmusson, R. Alharethi, et al.
Genome-wide sig-nificance and replication of the chromosome 12p11.22 locus near the pthlh gene for peripartum cardiomyopathy.
Circ Car-diovasc Genet, 4 (2011), pp. 359-366
[39]
K.Y. van Spaendonck-Zwarts, J.P. van Tintelen, D.J. van Veldhuisen, et al.
Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy.
Circulation, 121 (2010), pp. 2169-2175
[40]
Y.M. Hoedemaekers, K. Caliskan, M. Michels, et al.
The importance of genetic counseling, DNA diagnostics, and cardiologic fam-ily screening in left ventricular noncompaction cardiomyopathy.
Circ Cardiovasc Genet, 3 (2010), pp. 232-239
[41]
P. Elliott, C. O’Mahony, P. Syrris, et al.
Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopa-thy.
Circ Cardiovasc Genet, 3 (2010), pp. 314-322
[42]
P. Garcia-Pavia, P. Syrris, C. Salas, et al.
Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study.
Heart, 97 (2011), pp. 1744-1752
[43]
J. Cowan, D. Li, J. Gonzalez-Quintana, et al.
Morphological anal-ysis of 13 lmna variants identified in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy.
Circ Cardiovasc Genet, 3 (2010), pp. 6-14
[44]
C. Caleshu, S. Day, H.L. Rehm, et al.
Use and interpre-tation of genetic tests in cardiovascular genetics.
Heart, 96 (2010), pp. 1669-1675
[45]
G. Millat, P. Bouvagnet, P. Chevalier, et al.
Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy.
Eur J Med Genet, 54 (2011), pp. e570-e575
[46]
D.V. Moller, P.S. Andersen, P. Hedley, et al.
The role of sarcomere gene mutations in patients with idiopathic dilated cardiomy-opathy.
Eur J Hum Genet, 17 (2009), pp. 1241-1249
[47]
S. Probst, E. Oechslin, P. Schuler, et al.
Sarcomere gene muta-tions in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype.
Circ Cardiovasc Genet, 4 (2011), pp. 367-374
[48]
E. Rampersaud, J.D. Siegfried, N. Norton, et al.
Rare variant mutations identified in pediatric patients with dilated car-diomyopathy.
Prog Pediatr Cardiol, 31 (2011), pp. 39-47
[49]
C. Caleshu, R. Sakhuja, R.L. Nussbaum, et al.
Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated car-diomyopathy.
Am J Med Genet A, 155A (2011), pp. 2229-2235
[50]
J.P. Kaski, P. Syrris, M. Burch, et al.
Idiopathic restrictive cardiomy-opathy in children is caused by mutations in cardiac sarcomere protein genes.
Heart, 94 (2008), pp. 1478-1484
[51]
F. Girolami, C.Y. Ho, C. Semsarian, et al.
Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations.
J Am Coll Cardiol, 55 (2010), pp. 1444-1453
[52]
R.E. Hershberger, N. Norton, A. Morales, et al.
Coding sequence rare variants identified in mybpc3, myh6, tpm1, tnnc1, and tnni3 from 312 patients with familial or idiopathic dilated car-diomyopathy.
Circ Cardiovasc Genet, 3 (2010), pp. 155-161
[53]
E. Rampersaud, D.D. Kinnamon, K. Hamilton, et al.
Common susceptibility variants examined for association with dilated cardiomyopathy.
Ann Hum Genet, 74 (2010), pp. 110-116
[54]
T.Z. Armel, L.A. Leinwand.
Mutations at the same amino acid in myosin that cause either skeletal or cardiac myopa-thy have distinct molecular phenotypes.
J Mol Cell Cardiol, 48 (2010), pp. 1007-1013
[55]
M.G. Friedrich, U. Sechtem, J. Schulz-Menger, et al.
Cardiovascular magnetic resonance in myocarditis: a jacc white paper.
J Am Coll Cardiol, 53 (2009), pp. 1475-1487
[56]
P.A. Monney, N. Sekhri, T. Burchell, et al.
Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis.
Heart, 97 (2010), pp. 1312-1318
[57]
G. Leurent, B. Langella, C. Fougerou, et al.
Diagnostic contributions of cardiac magnetic resonance imaging in patients presenting with elevated troponin, acute chest pain syndrome and unobstructed coronary arteries.
Arch Cardiovasc Dis, 104 (2011), pp. 161-170
[58]
R.G. Assomull, S.K. Prasad, J. Lyne, et al.
Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy.
J Am Coll Cardiol, 48 (2006), pp. 1977-1985
[59]
S. Lehrke, D. Lossnitzer, M. Schob, et al.
Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy.
Heart, 97 (2011), pp. 727-732
[60]
Malaty AN, Shah DJ, Abdelkarim AR, et al. Relation of replacement fibrosis to left ventricular diastolic function in patients with dilated cardiomyopathy. J Am Soc Echocardiogr. 2011; 24:333-338, official publication of the American Society of Echocardiography.
[61]
Holmstrom M, Kivisto S, Helio T, et al. Late gadolinium enhanced cardiovascular magnetic resonance of lamin a/c gene mutation related dilated cardiomyopathy. J Cardiovasc Magn Reson. 2011; 13:30, official journal of the Society for Cardiovascular Magnetic Resonance.
[62]
G. Nucifora, G.D. Aquaro, A. Pingitore, et al.
Myocardial fibrosis in isolated left ventricular non-compaction and its relation to disease severity.
Eur J Heart Fail, 13 (2011), pp. 170-176
[63]
P. Alter, H. Rupp, P. Adams, et al.
Occurrence of late gadolinium enhancement is associated with increased left ventricular wall stress and mass in patients with non-ischaemic dilated cardiomyopathy.
Eur J Heart Fail, 13 (2011), pp. 937-944
[64]
K.C. Wu, R.G. Weiss, D.R. Thiemann, et al.
Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.
J Am Coll Cardiol, 51 (2008), pp. 2414-2421
[65]
K. Tigen, T. Karaahmet, C. Kirma, et al.
Diffuse late gadolinium enhancement by cardiovascular magnetic resonance predicts significant intraventricular systolic dyssynchrony in patients with non-ischemic dilated cardiomyopathy.
J Am Soc Echocardiogr, 23 (2010), pp. 416-422
[66]
F. Escher, D. Westermann, R. Gaub, et al.
Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis.
Heart, 97 (2011), pp. 709-714
[67]
Dickstein K, Vardas PE, Auricchio A, et al. 2010 focused update of esc guidelines on device therapy in heart failure: an update of the 2008 esc guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 esc guide-lines for cardiac and resynchronization therapy. Developed with the special contribution of the heart failure association and the european heart rhythm association. Eur Heart J. 2010; 31: 2677–87.
[68]
D.M. McNamara, R.C. Starling, L.T. Cooper, et al.
Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy results of the IMAC (intervention in myocarditis and acute cardiomyopathy)-2 study.
J Am Coll Cardiol, 58 (2011), pp. 1112-1118
[69]
A. Verma, Z. Wulffhart, D. Lakkireddy, et al.
Incidence of left ventricular function improvement after primary prevention icd implantation for non-ischaemic dilated cardiomyopathy: a multicentre experience.
Heart, 96 (2010), pp. 510-515
[70]
C. Meune, J.H. Van Berlo, F. Anselme, et al.
Primary prevention of sudden death in patients with lamin a/c gene mutations.
N Engl J Med, 354 (2006), pp. 209-210
[71]
E.M. McNally, D. Sparano.
Mechanisms and management of the heart in myotonic dystrophy.
Heart, 97 (2011), pp. 1094-1100
[72]
B. Lallemand, N. Clementy, A.B. Brunet, et al.
The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implications.
[73]
R.J. van Bommel, N.A. Marsan, V. Delgado, et al.
Cardiac resyn-chronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high oper-ative risk.
Circulation, 124 (2011), pp. 912-919
[74]
A. Rossi, F.L. Dini, P. Faggiano, et al.
Independent prognostic value of functional mitral regurgitation in patients with heart fail-ure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy.
Heart, 97 (2011), pp. 1675-1680
[75]
M. Bertini, M. Ziacchi, M. Biffi, et al.
Effects of cardiac resyn-chronisation therapy on dilated cardiomyopathy with isolated ventricular non-compaction.
Heart, 97 (2011), pp. 295-300
[76]
E. Agricola, M. Oppizzi, M. Galderisi, et al.
Role of regional mechanical dyssynchrony as a determinant of functional mitral regurgitation in patients with left ventricular systolic dysfunc-tion.
Heart, 92 (2006), pp. 1390-1395
[77]
Donal E, De Place C, Kervio G, et al. Mitral regurgitation in dilated cardiomyopathy: value of both regional left ven-tricular contractility and dyssynchrony. Eur J Echocardiogr. 2009; 10:133-138, the journal of the Working Gro**up on Echocar-diography of the European Society of Cardiology.
[78]
C. Chiu, R.D. Bagnall, J. Ingles, et al.
Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis.
J Am Coll Cardiol, 55 (2010), pp. 1127-1135
[79]
K.M. Brauch, M.L. Karst, K.J. Herron, et al.
Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopa-thy.
J Am Coll Cardiol, 54 (2009), pp. 930-941
[80]
A. Morales, T. Painter, R. Li, et al.
Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy.
Circulation, 121 (2010), pp. 2176-2182
[81]
T. Arimura, J.M. Bos, A. Sato, et al.
Cardiac ankyrin repeat protein gene (ankrd1) mutations in hypertrophic cardiomyopathy.
J Am Coll Cardiol, 54 (2009), pp. 334-342
[82]
M. Moulik, M. Vatta, S.H. Witt, et al.
Ankrd1, the gene encoding car-diac ankyrin repeat protein, is a novel dilated cardiomyopathy gene.
J Am Coll Cardiol, 54 (2009), pp. 325-333
[83]
E. Villard, C. Perret, F. Gary, et al.
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy.
Eur Heart J, 32 (2011), pp. 1065-1076
[84]
N. Norton, D. Li, M.J. Rieder, et al.
Genome-wide studies of copy number variation and exome sequencing identify rare variants in bag3 as a cause of dilated cardiomyopathy.
Am J Hum Genet, 88 (2011), pp. 273-282
[85]
G.G. Neely, K. Kuba, A. Cammarato, et al.
A global in vivo drosophila rnai screen identifies not3 as a conserved regulator of heart function.
[86]
K.V. Voelkerding, S. Dames, J.D. Durtschi.
Next generation sequencing for clinical diagnostics-principles and application to targeted resequencing for hypertrophic cardiomyopathy: a paper from the 2009 william beaumont hospital symposium on molecular pathology.
J Mol Diagn, 12 (2010), pp. 539-551
[87]
J.S. Ware, A.M. Roberts, S.A. Cook.
Next generation sequencing for clinical diagnostics and personalised medicine: implications for the next generation cardiologist.
[88]
S. Dames, J. Durtschi, K. Geiersbach, et al.
Comparison of the illu-mina genome analyzer and roche 454 gs flx for resequencing of hypertrophic cardiomyopathy-associated genes.
J Biomol Tech, 21 (2010), pp. 73-80
[89]
B. Meder, J. Haas, A. Keller, et al.
Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomy-opathies.
Circ Cardiovasc Genet, 4 (2011), pp. 110-122
[90]
S. Gowrisankar, J.P. Lerner-Ellis, S. Cox, et al.
Evaluation of second-generation sequencing of 19 dilated cardiomyopa-thy genes for clinical applications.
J Mol Diagnost, 12 (2010), pp. 818-827

Secondary publication: This article was published in its entirety, with the consent of the authors and editors, in Heart. 2011;97:1914–9.

Copyright © 2012. Sociedade Portuguesa de Cardiologia
Idiomas
Revista Portuguesa de Cardiologia (English edition)

Subscribe to our newsletter

Article options
Tools
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

By checking that you are a health professional, you are stating that you are aware and accept that the Portuguese Journal of Cardiology (RPC) is the Data Controller that processes the personal information of users of its website, with its registered office at Campo Grande, n.º 28, 13.º, 1700-093 Lisbon, telephone 217 970 685 and 217 817 630, fax 217 931 095, and email revista@spc.pt. I declare for all purposes that the information provided herein is accurate and correct.